Last updated: July 28, 2026
RELAFEN (nabumetone) investment scenario and patent/IP fundamentals analysis: exclusivity, Orange Book status, litigation, and generic risk
Relafen (nabumetone) is an older nonsteroidal anti-inflammatory drug (NSAID) with limited new-IP upside in most markets because the core active-ingredient patent estate is expired and long-established generic competition has already formed in major jurisdictions. Investment fundamentals are therefore driven less by “patent-protected growth” and more by: (1) remaining brand share and pricing in specific geographies, (2) any surviving formulation/method-of-use patents that could slow generic switching, and (3) regulatory and manufacturing execution that avoids market-access friction.
No complete, jurisdiction-specific patent and FDA Orange Book dataset for “Relafen (nabumetone)” is provided in the prompt, so this analysis is constrained to high-level fundamentals and generic entry risk frameworks for an established small-molecule NSAID whose active ingredient is expected to be beyond primary exclusivity.
Is Relafen still protected by patents in the US, and when do nabumetone patents expire?
Core point: For established small-molecule NSAIDs like nabumetone, the active ingredient’s primary composition-of-matter protection is typically long expired, with any remaining barriers coming from secondary IP such as formulations, specific crystalline forms, dosage regimens, or device-adjacent packaging.
What investors look for
- Orange Book listings tied to approved nabumetone products. These list patent numbers, exclusivity codes, and expiration dates.
- Secondary patents that still have enforceable terms (often formulations, process, or polymorph claims).
- Method-of-use patents if the current approved label supports a narrower, still-protected indication or dosing scheme.
US expiration reality check (framework)
- If the Orange Book shows only inactive/expired patents and no unexpired listed patents for the currently marketed NDA/BLA, market-access risk for generics is materially lower because Paragraph IV leverage disappears.
- If any unexpired listed patents remain, generic entry can be delayed through litigation or settlement.
What is the Orange Book status of Relafen (nabumetone) and how many patents are listed?
Featured snippet answer: Orange Book status determines whether generics can file ANDA with certification risk under 21 U.S.C. §355(j)(2)(A) through (B) and (C).
Investment mapping
- “Patent-free” Orange Book scenarios are typical for older NSAIDs and imply:
- high likelihood of generic parity dosing soon after market-entry,
- limited pricing power beyond channel-specific dynamics.
- Active Orange Book listings imply:
- potential Paragraph IV challenges,
- settlement-driven delayed entries,
- ongoing patent thickets for specific strengths/dosage forms (e.g., 500 mg vs 750 mg).
Data needed for a precise count
A complete Orange Book extract (patent numbers, expiration dates, Orange Book NDA labeler and dosage-form linkages). The prompt does not include that dataset.
How strong is the patent estate for Relafen nabumetone formulations, and what patent types matter?
Core point: For a mature NSAID, investor-grade strength analysis focuses on whether any unexpired patents address:
- Formulation (controlled release, improved dissolution, specific excipient systems, particle size, tablet hardness windows)
- Crystalline form/polymorph (if applicable to nabumetone)
- Manufacturing processes (process parameters, solvent systems, crystallization conditions)
- Methods of use (specific patient subpopulations, dosing schedules, or combination regimens)
Typical outcomes
- If only expired composition-of-matter patents remain, enforceable exclusivity is weak.
- If unexpired formulation/process patents exist, they can support modest premium pricing or protect specific product line economics, but they rarely drive category-wide growth unless they block key bioequivalence routes.
Investor diligence checklist (IP)
- Patent claim scope relative to likely generic design space
- Freedom-to-operate risk for:
- tablet excipient selection,
- process parameters,
- dissolution profile targets,
- particle size distribution
- History of enforcement or licensing for the specific dosage strengths.
What generic entry risks exist for nabumetone, and how do Paragraph IV challenges affect timing?
Core point: For an older NSAID, the primary generic entry risk often shifts from “new Paragraph IV fights” to “incremental market share capture” by additional labelers once any active barriers fall.
Timing mechanics
- Patent-protected entry: Generics with Paragraph IV certifications may face an automatic stay if sued within statutory timelines; settlement can extend the delay.
- Patent-expired entry: ANDAs can transition to approvals and launches with less friction, causing rapid price compression.
What changes the investment case
- Unexpired listed patents for a given dosage form can create a short-lived “delay window.”
- If no enforceable listings remain, generic entry tends to be fast and price-driven.
What patent litigation affects Relafen (nabumetone), and which companies are challenging it?
Core point: Litigation is a double-edged indicator for investors:
- It can extend brand cash flows if settlements delay generics.
- It also signals ongoing demand for commercial substitution routes, which typically pressures pricing.
What to look for in case dockets
- Filed ANDAs with Paragraph IV certifications referencing specific listed patents
- Court outcomes (dismissals, claim constructions, summary judgment)
- Settlement agreement terms:
- “Agreed launch date”
- “Territory carve-outs”
- “Design-around” restrictions
- Supply arrangements.
Data gap
The prompt does not include litigation docket identifiers or party names. Without a docket list and Orange Book-linked patents, a company-specific litigation map cannot be produced.
How does Relafen compare with other NSAIDs on investment fundamentals: patent lifetime, generic saturation, and pricing power?
Core point: Mature NSAID brands generally share the same pattern:
- high generic saturation after patent expiry,
- limited additional exclusivity unless formulation/process innovations exist,
- growth is driven by brand retention, contracting, and payer dynamics.
Relafen positioning considerations
- If Relafen’s market is dominated by generics, brand value is usually tied to:
- formularies and managed care access,
- pharmacy distribution contracts,
- substitution limits or clinician preference,
- regional competitive intensity.
Benchmark comparison approach (investor-ready)
- Compare:
- US NDC-level shares and net price trends,
- wholesaler inventory and rebate structure,
- relative generic penetration across strengths,
- enforcement history of secondary patents (if any).
What formulation patents protect Relafen, and do they block generic bioequivalence?
Core point: A generic ANDA bypasses most formulation IP unless the claims specifically cover a structure that must be matched to achieve bioequivalence or unless design-around is constrained by claim scope.
How to assess blocking potential
- If patents claim specific excipient systems or manufacturing parameters, generics can often design around unless claims are narrow and difficult to avoid.
- If patents claim a protected intermediate or unique crystalline state that affects dissolution/absorption, blocking risk rises.
- If patents are broad but tied to facts specific to a process, enforcement becomes harder unless infringement proof is clear.
Data needed
Unexpired formulation/polymorph/process patents and claim language. No patent list is provided.
Are biosimilars relevant to Relafen’s investment case?
Core point: Biosimilars are not relevant because Relafen is a small molecule (nabumetone), not a biologic. The competitive risk comes from chemical generics and, in some cases, different NSAID classes rather than biosimilar substitution.
Regulatory pathway: what FDA status matters for generic nabumetone entry?
Core point: Entry depends on:
- ANDA approvals for nabumetone strengths and dosage forms,
- whether any application is tied to unexpired listed patents,
- any ongoing FDA or court-linked exclusivity constraints.
Investment implication
- With an established NSAID, market access friction is generally low once patent barriers are removed.
- Regulatory execution is not the differentiator; commercial contracting and product availability are.
Revenue exposure and downside drivers: how much brand value can survive after generic erosion?
Core point: Brand erosion in mature NSAIDs usually follows:
- step-down in net price after generic launches,
- rebate pressure and payer preference shifts,
- loss of shelf space and increased substitution at the pharmacy counter.
Downside drivers
- Rapid increase in generic number of suppliers leading to aggressive pricing
- Contracting pressure from large PBMs
- Channel inventory dynamics that trigger wholesaler price adjustments
Upside drivers
- Any remaining unexpired listed patents that delay additional generic entry
- Specialty formulary placement or restricted substitution policies
- Continued differentiation through brand reputation and clinician habits (usually modest once generics dominate)
Key takeaways
- Relafen (nabumetone) investment case is primarily a mature-brands, managed-competition story rather than a “patent-led growth” story.
- Patent/IP upside typically hinges on whether any unexpired Orange Book-listed secondary patents remain for specific dosage forms.
- Generic entry timing and price compression depend on listed-patent status and any Paragraph IV litigation or settlements.
- Biosimilars are not relevant; competitive threat is chemical generics and substitution within NSAID therapeutic classes.
FAQs
- What drives net price erosion for established NSAID brands like Relafen after generic entry?
- How do formulation and process patents typically influence generic switching for immediate-release tablets?
- What settlement terms most affect launch timing in Paragraph IV disputes for small molecules?
- How should investors evaluate Orange Book patent relevance versus claim scope and design-around feasibility?
- What payer and PBM contracting levers most impact brand retention for generic-saturated NSAID markets?
References
No source material was provided in the prompt (no FDA Orange Book extract, no patent list, no court docket references, no company filings). Therefore, no citable references can be generated for a precise, patent-number-backed analysis.
